FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer


Ad hoc announcement pursuant to Art. 53 LR

More here:
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer

Related Posts